<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34488813</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>06</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>Wild-type FUS corrects ALS-like disease induced by cytoplasmic mutant FUS through autoregulation.</ArticleTitle><Pagination><StartPage>61</StartPage><MedlinePgn>61</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">61</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13024-021-00477-w</ELocationID><Abstract><AbstractText>Mutations in FUS, an RNA-binding protein involved in multiple steps of RNA metabolism, are associated with the most severe forms of amyotrophic lateral sclerosis (ALS). Accumulation of cytoplasmic FUS is likely to be a major culprit in the toxicity of FUS mutations. Thus, preventing cytoplasmic mislocalization of the FUS protein may represent a valuable therapeutic strategy. FUS binds to its own pre-mRNA creating an autoregulatory loop efficiently buffering FUS excess through multiple proposed mechanisms including retention of introns 6 and/or 7. Here, we introduced a wild-type FUS gene allele, retaining all intronic sequences, in mice whose heterozygous or homozygous expression of a cytoplasmically retained FUS protein (Fus<sup>&#x2206;NLS</sup>) was previously shown to provoke ALS-like disease or postnatal lethality, respectively. Wild-type FUS completely rescued the early lethality caused by the two Fus<sup>&#x2206;NLS</sup> alleles, and improved the age-dependent motor deficits and reduced lifespan caused by heterozygous expression of mutant FUS<sup>&#x2206;NLS</sup>. Mechanistically, wild-type FUS decreased the load of cytoplasmic FUS, increased retention of introns 6 and 7 in the endogenous mouse Fus mRNA, and decreased expression of the mutant mRNA. Thus, the wild-type FUS allele activates the homeostatic autoregulatory loop, maintaining constant FUS levels and decreasing the mutant protein in the cytoplasm. These results provide proof of concept that an autoregulatory competent wild-type FUS expression could protect against this devastating, currently intractable, neurodegenerative disease.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sanjuan-Ruiz</LastName><ForeName>Inmaculada</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>M&#xe9;canismes centraux et p&#xe9;riph&#xe9;riques de la neurod&#xe9;g&#xe9;n&#xe9;rescence, Centre de Recherches en Biom&#xe9;decine, Universit&#xe9; de Strasbourg, Inserm, UMR-S1118, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Govea-Perez</LastName><ForeName>No&#xe9;</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>McAlonis-Downes</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dieterle</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>M&#xe9;canismes centraux et p&#xe9;riph&#xe9;riques de la neurod&#xe9;g&#xe9;n&#xe9;rescence, Centre de Recherches en Biom&#xe9;decine, Universit&#xe9; de Strasbourg, Inserm, UMR-S1118, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Megat</LastName><ForeName>Salim</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>M&#xe9;canismes centraux et p&#xe9;riph&#xe9;riques de la neurod&#xe9;g&#xe9;n&#xe9;rescence, Centre de Recherches en Biom&#xe9;decine, Universit&#xe9; de Strasbourg, Inserm, UMR-S1118, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dirrig-Grosch</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>M&#xe9;canismes centraux et p&#xe9;riph&#xe9;riques de la neurod&#xe9;g&#xe9;n&#xe9;rescence, Centre de Recherches en Biom&#xe9;decine, Universit&#xe9; de Strasbourg, Inserm, UMR-S1118, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Picchiarelli</LastName><ForeName>Gina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>M&#xe9;canismes centraux et p&#xe9;riph&#xe9;riques de la neurod&#xe9;g&#xe9;n&#xe9;rescence, Centre de Recherches en Biom&#xe9;decine, Universit&#xe9; de Strasbourg, Inserm, UMR-S1118, Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piol</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain and Disease Research, Department of Neurosciences, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myers</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Chao-Zong</ForeName><Initials>CZ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, The Sean M. Healey and AMG Center for ALS at Mass General, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of Harvard University and MIT, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cleveland</LastName><ForeName>Don W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lagier-Tourenne</LastName><ForeName>Clotilde</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, The Sean M. Healey and AMG Center for ALS at Mass General, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Broad Institute of Harvard University and MIT, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Da Cruz</LastName><ForeName>Sandrine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research, University of California at San Diego, La Jolla, USA. sandrine.dacruz@kuleuven.be.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VIB-KU Leuven Center for Brain and Disease Research, Department of Neurosciences, KU Leuven, Leuven, Belgium. sandrine.dacruz@kuleuven.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dupuis</LastName><ForeName>Luc</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>M&#xe9;canismes centraux et p&#xe9;riph&#xe9;riques de la neurod&#xe9;g&#xe9;n&#xe9;rescence, Centre de Recherches en Biom&#xe9;decine, Universit&#xe9; de Strasbourg, Inserm, UMR-S1118, Strasbourg, France. ldupuis@unistra.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DUPUIS/APR16/852-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 NS108769</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000599550">FUS protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000599551">FUS protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012322">RNA Precursors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005804" MajorTopicYN="N">Genes, Lethal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005816" MajorTopicYN="N">Genetic Complementation Test</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007438" MajorTopicYN="N">Introns</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012322" MajorTopicYN="N">RNA Precursors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019076" MajorTopicYN="N">Transgenes</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Autoregulation</Keyword><Keyword MajorTopicYN="N">FUS</Keyword><Keyword MajorTopicYN="N">Fronto-temporal dementia</Keyword><Keyword MajorTopicYN="N">Mouse models</Keyword><Keyword MajorTopicYN="N">RNA-binding proteins</Keyword><Keyword MajorTopicYN="N">Therapy</Keyword></KeywordList><CoiStatement>ISR, GP and LD filed a European patent application partially based on results included in this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34488813</ArticleId><ArticleId IdType="pmc">PMC8419956</ArticleId><ArticleId IdType="doi">10.1186/s13024-021-00477-w</ArticleId><ArticleId IdType="pii">10.1186/s13024-021-00477-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390(10107):2084&#x2013;98. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Jr, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 2017;377(2):162&#x2013;72. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Waibel S, Neumann M, Rabe M, Meyer T, Ludolph AC. Novel missense and truncating mutations in FUS/TLS in familial ALS. Neurology. 2010;75(9):815&#x2013;7. doi: 10.1212/WNL.0b013e3181f07e26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181f07e26</ArticleId><ArticleId IdType="pubmed">20660363</ArticleId></ArticleIdList></Reference><Reference><Citation>Waibel S, Neumann M, Rosenbohm A, Birve A, Volk AE, Weishaupt JH, et al. Truncating mutations in FUS/TLS give rise to a more aggressive ALS-phenotype than missense mutations: a clinico-genetic study in Germany. Eur J Neurol. 2013;20(3):540&#x2013;6. doi: 10.1111/ene.12031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12031</ArticleId><ArticleId IdType="pubmed">23217123</ArticleId></ArticleIdList></Reference><Reference><Citation>Dormann D, Madl T, Valori CF, Bentmann E, Tahirovic S, Abou-Ajram C, et al. Arginine methylation next to the PY-NLS modulates Transportin binding and nuclear import of FUS. EMBO J. 2012;31(22):4258&#x2013;75. doi: 10.1038/emboj.2012.261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2012.261</ArticleId><ArticleId IdType="pmc">PMC3501225</ArticleId><ArticleId IdType="pubmed">22968170</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez-Calvet M, Neumann M, Arzberger T, Abou-Ajram C, Funk E, Hartmann H, et al. Monomethylated and unmethylated FUS exhibit increased binding to Transportin and distinguish FTLD-FUS from ALS-FUS. Acta Neuropathol. 2016;131(4):587&#x2013;604. doi: 10.1007/s00401-016-1544-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1544-2</ArticleId><ArticleId IdType="pubmed">26895297</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S, Ling SC, Qiu J, Albuquerque CP, Zhou Y, Tokunaga S, et al. ALS-causative mutations in FUS/TLS confer gain and loss of function by altered association with SMN and U1-snRNP. Nat Commun. 2015;6:6171. doi: 10.1038/ncomms7171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms7171</ArticleId><ArticleId IdType="pmc">PMC4338613</ArticleId><ArticleId IdType="pubmed">25625564</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Erauskin J, Tadokoro T, Baughn MW, Myers B, McAlonis-Downes M, Chillon-Marinas C, et al. ALS/FTD-Linked Mutation in FUS Suppresses Intra-axonal Protein Synthesis and Drives Disease Without Nuclear Loss-of-Function of FUS. Neuron. 2018;100(4):816&#x2013;30. doi: 10.1016/j.neuron.2018.09.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.09.044</ArticleId><ArticleId IdType="pmc">PMC6277851</ArticleId><ArticleId IdType="pubmed">30344044</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Dastidar SG, Tokunaga S, Ho WY, Lim K, Ilieva H, et al. Overriding FUS autoregulation in mice triggers gain-of-toxic dysfunctions in RNA metabolism and autophagy-lysosome axis. eLife. 2019;8:e40811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6389288</ArticleId><ArticleId IdType="pubmed">30747709</ArticleId></ArticleIdList></Reference><Reference><Citation>Devoy A, Kalmar B, Stewart M, Park H, Burke B, Noy SJ, et al. Humanized mutant FUS drives progressive motor neuron degeneration without aggregation in &#x2018;FUSDelta14&#x2019; knockin mice. Brain. 2017;140(11):2797&#x2013;805. doi: 10.1093/brain/awx248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx248</ArticleId><ArticleId IdType="pmc">PMC5841203</ArticleId><ArticleId IdType="pubmed">29053787</ArticleId></ArticleIdList></Reference><Reference><Citation>Scekic-Zahirovic J, Sendscheid O, El Oussini H, Jambeau M, Sun Y, Mersmann S, et al. Toxic gain of function from mutant FUS protein is crucial to trigger cell autonomous motor neuron loss. EMBO J. 2016;35(10):1077&#x2013;97. doi: 10.15252/embj.201592559.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201592559</ArticleId><ArticleId IdType="pmc">PMC4868956</ArticleId><ArticleId IdType="pubmed">26951610</ArticleId></ArticleIdList></Reference><Reference><Citation>Scekic-Zahirovic J, Oussini HE, Mersmann S, Drenner K, Wagner M, Sun Y, et al. Motor neuron intrinsic and extrinsic mechanisms contribute to the pathogenesis of FUS-associated amyotrophic lateral sclerosis. Acta Neuropathol. 2017;133(6):887&#x2013;906. doi: 10.1007/s00401-017-1687-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1687-9</ArticleId><ArticleId IdType="pmc">PMC5427169</ArticleId><ArticleId IdType="pubmed">28243725</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrone L, Drexler HCA, Wang J, Tripathi P, Distler T, Heisterkamp P, et al. FUS pathology in ALS is linked to alterations in multiple ALS-associated proteins and rescued by drugs stimulating autophagy. Acta Neuropathol. 2019;138(1):67&#x2013;84. doi: 10.1007/s00401-019-01998-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-01998-x</ArticleId><ArticleId IdType="pmc">PMC6570784</ArticleId><ArticleId IdType="pubmed">30937520</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphrey J, Birsa N, Milioto C, McLaughlin M, Ule AM, Robaldo D, et al. FUS ALS-causative mutations impair FUS autoregulation and splicing factor networks through intron retention. Nucleic Acids Res. 2020;48(12):6889&#x2013;905. doi: 10.1093/nar/gkaa410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa410</ArticleId><ArticleId IdType="pmc">PMC7337901</ArticleId><ArticleId IdType="pubmed">32479602</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Liu S, Liu G, Ozturk A, Hicks GG. ALS-associated FUS mutations result in compromised FUS alternative splicing and autoregulation. PLoS Genet. 2013;9(10):e1003895. doi: 10.1371/journal.pgen.1003895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1003895</ArticleId><ArticleId IdType="pmc">PMC3814325</ArticleId><ArticleId IdType="pubmed">24204307</ArticleId></ArticleIdList></Reference><Reference><Citation>Dini Modigliani S, Morlando M, Errichelli L, Sabatelli M, Bozzoni I. An ALS-associated mutation in the FUS 3&#x2019;-UTR disrupts a microRNA-FUS regulatory circuitry. Nat Commun. 2014;5:4335. doi: 10.1038/ncomms5335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms5335</ArticleId><ArticleId IdType="pubmed">25004804</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell JC, McGoldrick P, Vance C, Hortobagyi T, Sreedharan J, Rogelj B, et al. Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion. Acta Neuropathol. 2013;125(2):273&#x2013;88. doi: 10.1007/s00401-012-1043-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1043-z</ArticleId><ArticleId IdType="pmc">PMC3549237</ArticleId><ArticleId IdType="pubmed">22961620</ArticleId></ArticleIdList></Reference><Reference><Citation>Scekic-Zahirovic J, Sanjuan-Ruiz I, Kan V, Megat S, De Rossi P, Dieterle S, et al. Cytoplasmic FUS triggers early behavioral alterations linked to cortical neuronal hyperactivity and inhibitory synaptic defects. Nat Commun. 2021;12:3028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8140148</ArticleId><ArticleId IdType="pubmed">34021132</ArticleId></ArticleIdList></Reference><Reference><Citation>Dormann D, Rodde R, Edbauer D, Bentmann E, Fischer I, Hruscha A, et al. ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J. 2010;29(16):2841&#x2013;57. doi: 10.1038/emboj.2010.143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2010.143</ArticleId><ArticleId IdType="pmc">PMC2924641</ArticleId><ArticleId IdType="pubmed">20606625</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Polymenidou M, Hutt KR, Vu AQ, Baughn M, Huelga SC, et al. Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat Neurosci. 2012;15(11):1488&#x2013;97. doi: 10.1038/nn.3230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3230</ArticleId><ArticleId IdType="pmc">PMC3586380</ArticleId><ArticleId IdType="pubmed">23023293</ArticleId></ArticleIdList></Reference><Reference><Citation>Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008;9(6):582&#x2013;9. doi: 10.1038/embor.2008.74.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/embor.2008.74</ArticleId><ArticleId IdType="pmc">PMC2396950</ArticleId><ArticleId IdType="pubmed">18483486</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008;22(7):894&#x2013;907. doi: 10.1101/gad.1640608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.1640608</ArticleId><ArticleId IdType="pmc">PMC2279201</ArticleId><ArticleId IdType="pubmed">18381893</ArticleId></ArticleIdList></Reference><Reference><Citation>Sephton CF, Tang AA, Kulkarni A, West J, Brooks M, Stubblefield JJ, et al. Activity-dependent FUS dysregulation disrupts synaptic homeostasis. Proc Natl Acad Sci U S A. 2014;111(44):E4769-78. doi: 10.1073/pnas.1406162111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1406162111</ArticleId><ArticleId IdType="pmc">PMC4226112</ArticleId><ArticleId IdType="pubmed">25324524</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez A, Mannen T, Cagatay T, Fujiwara A, Matsumura H, Niesman AB, et al. Mechanism of karyopherin-beta2 binding and nuclear import of ALS variants FUS(P525L) and FUS(R495X) Sci Rep. 2021;11(1):3754. doi: 10.1038/s41598-021-83196-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-83196-y</ArticleId><ArticleId IdType="pmc">PMC7881136</ArticleId><ArticleId IdType="pubmed">33580145</ArticleId></ArticleIdList></Reference><Reference><Citation>Baade I, Hutten S, Sternburg EL, Porschke M, Hofweber M, Dormann D, et al. The RNA-binding protein FUS is chaperoned and imported into the nucleus by a network of import receptors. J Biol Chem. 2021:100659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8131929</ArticleId><ArticleId IdType="pubmed">33857479</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, Scotter EL, Nishimura AL, Troakes C, Mitchell JC, Kathe C, et al. ALS mutant FUS disrupts nuclear localisation and sequesters wild-type FUS within cytoplasmic stress granules. Hum Mol Genet. 2013;22:2676-88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3674807</ArticleId><ArticleId IdType="pubmed">23474818</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Alstyne M, Tattoli I, Delestree N, Recinos Y, Workman E, Shihabuddin LS, et al. Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit. Nat Neurosci. 2021;24:930&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8254787</ArticleId><ArticleId IdType="pubmed">33795885</ArticleId></ArticleIdList></Reference><Reference><Citation>Kino Y, Washizu C, Kurosawa M, Yamada M, Miyazaki H, Akagi T, et al. FUS/TLS deficiency causes behavioral and pathological abnormalities distinct from amyotrophic lateral sclerosis. Acta neuropathologica communications. 2015;3:24. doi: 10.1186/s40478-015-0202-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-015-0202-6</ArticleId><ArticleId IdType="pmc">PMC4408580</ArticleId><ArticleId IdType="pubmed">25907258</ArticleId></ArticleIdList></Reference><Reference><Citation>Orozco D, Tahirovic S, Rentzsch K, Schwenk BM, Haass C, Edbauer D. Loss of fused in sarcoma (FUS) promotes pathological Tau splicing. EMBO Rep. 2012;13(8):759&#x2013;64. doi: 10.1038/embor.2012.90.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/embor.2012.90</ArticleId><ArticleId IdType="pmc">PMC3410390</ArticleId><ArticleId IdType="pubmed">22710833</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishigaki S, Fujioka Y, Okada Y, Riku Y, Udagawa T, Honda D, et al. Altered Tau Isoform Ratio Caused by Loss of FUS and SFPQ Function Leads to FTLD-like Phenotypes. Cell Rep. 2017;18(5):1118&#x2013;31. doi: 10.1016/j.celrep.2017.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.01.013</ArticleId><ArticleId IdType="pubmed">28147269</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoi S, Udagawa T, Fujioka Y, Honda D, Okado H, Watanabe H, et al. 3&#x2019;UTR Length-Dependent Control of SynGAP Isoform alpha2 mRNA by FUS and ELAV-like Proteins Promotes Dendritic Spine Maturation and Cognitive Function. Cell Rep. 2017;20(13):3071&#x2013;84. doi: 10.1016/j.celrep.2017.08.100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.08.100</ArticleId><ArticleId IdType="pubmed">28954225</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishigaki S, Sobue G. Importance of Functional Loss of FUS in FTLD/ALS. Front Mol Biosci. 2018;5:44. doi: 10.3389/fmolb.2018.00044.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2018.00044</ArticleId><ArticleId IdType="pmc">PMC5943504</ArticleId><ArticleId IdType="pubmed">29774215</ArticleId></ArticleIdList></Reference><Reference><Citation>Huey ED, Ferrari R, Moreno JH, Jensen C, Morris CM, Potocnik F, et al. FUS and TDP43 genetic variability in FTD and CBS. Neurobiol Aging. 2012;33(5):1016 e9&#x2013;17. doi: 10.1016/j.neurobiolaging.2011.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.08.004</ArticleId><ArticleId IdType="pmc">PMC4489700</ArticleId><ArticleId IdType="pubmed">21943958</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Langenhove T, van der Zee J, Sleegers K, Engelborghs S, Vandenberghe R, Gijselinck I, et al. Genetic contribution of FUS to frontotemporal lobar degeneration. Neurology. 2010;74(5):366&#x2013;71. doi: 10.1212/WNL.0b013e3181ccc732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181ccc732</ArticleId><ArticleId IdType="pubmed">20124201</ArticleId></ArticleIdList></Reference><Reference><Citation>Broustal O, Camuzat A, Guillot-Noel L, Guy N, Millecamps S, Deffond D, et al. FUS mutations in frontotemporal lobar degeneration with amyotrophic lateral sclerosis. J Alzheimers Dis. 2010;22(3):765&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">21158017</ArticleId></ArticleIdList></Reference><Reference><Citation>Flies CM, Veldink JH. Chorea is a pleiotropic clinical feature of mutated fused-in-sarcoma in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:309-11.</Citation><ArticleIdList><ArticleId IdType="pubmed">32116048</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita S, Mori A, Sakaguchi H, Suga T, Ishihara D, Ueda A, et al. Sporadic juvenile amyotrophic lateral sclerosis caused by mutant FUS/TLS: possible association of mental retardation with this mutation. J Neurol. 2012;259(6):1039&#x2013;44. doi: 10.1007/s00415-011-6292-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-011-6292-6</ArticleId><ArticleId IdType="pubmed">22057404</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan J, Deng HX, Siddique N, Fecto F, Chen W, Yang Y, et al. Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia. Neurology. 2010;75(9):807&#x2013;14. doi: 10.1212/WNL.0b013e3181f07e0c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181f07e0c</ArticleId><ArticleId IdType="pmc">PMC2938970</ArticleId><ArticleId IdType="pubmed">20668259</ArticleId></ArticleIdList></Reference><Reference><Citation>Merner ND, Girard SL, Catoire H, Bourassa CV, Belzil VV, Riviere JB, et al. Exome sequencing identifies FUS mutations as a cause of essential tremor. Am J Hum Genet. 2012;91(2):313&#x2013;9. doi: 10.1016/j.ajhg.2012.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2012.07.002</ArticleId><ArticleId IdType="pmc">PMC3415547</ArticleId><ArticleId IdType="pubmed">22863194</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyzack GE, Luisier R, Taha DM, Neeves J, Modic M, Mitchell JS, et al. Widespread FUS mislocalization is a molecular hallmark of amyotrophic lateral sclerosis. Brain. 2019;142(9):2572&#x2013;80. doi: 10.1093/brain/awz217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz217</ArticleId><ArticleId IdType="pmc">PMC6735815</ArticleId><ArticleId IdType="pubmed">31368485</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng HX, Zhai H, Bigio EH, Yan J, Fecto F, Ajroud K, et al. FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. Ann Neurol. 2010;67(6):739&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4376270</ArticleId><ArticleId IdType="pubmed">20517935</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikenaka K, Ishigaki S, Iguchi Y, Kawai K, Fujioka Y, Yokoi S, et al. Characteristic Features of FUS Inclusions in Spinal Motor Neurons of Sporadic Amyotrophic Lateral Sclerosis. J Neuropathol Exp Neurol. 2020;79:370-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32142134</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden JS, Hu Q, Rollinson S, Halliwell N, Robinson A, Davidson YS, et al. The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene. Acta Neuropathol. 2011;122(1):99&#x2013;110. doi: 10.1007/s00401-011-0816-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0816-0</ArticleId><ArticleId IdType="pubmed">21424531</ArticleId></ArticleIdList></Reference><Reference><Citation>Seelaar H, Klijnsma KY, de Koning I, van der Lugt A, Chiu WZ, Azmani A, et al. Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration. J Neurol. 2010;257(5):747&#x2013;53. doi: 10.1007/s00415-009-5404-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-009-5404-z</ArticleId><ArticleId IdType="pmc">PMC2864899</ArticleId><ArticleId IdType="pubmed">19946779</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Parisi JE, Petersen RC, Boeve BF, Jack CR, Jr, et al. Caudate atrophy on MRI is a characteristic feature of FTLD-FUS. Eur J Neurol. 2010;17(7):969&#x2013;75. doi: 10.1111/j.1468-1331.2010.02975.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2010.02975.x</ArticleId><ArticleId IdType="pmc">PMC2989679</ArticleId><ArticleId IdType="pubmed">20236174</ArticleId></ArticleIdList></Reference><Reference><Citation>Doi H, Koyano S, Suzuki Y, Nukina N, Kuroiwa Y. The RNA-binding protein FUS/TLS is a common aggregate-interacting protein in polyglutamine diseases. Neurosci Res. 2010;66(1):131&#x2013;3. doi: 10.1016/j.neures.2009.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2009.10.004</ArticleId><ArticleId IdType="pubmed">19833157</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori S, Honda H, Ishii T, Yoshimura M, Sasagasako N, Suzuki SO, et al. Expanded polyglutamine impairs normal nuclear distribution of fused in sarcoma and poly (rC)-binding protein 1 in Huntington&#x2019;s disease. Neuropathology. 2019;39(5):358&#x2013;67. doi: 10.1111/neup.12600.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12600</ArticleId><ArticleId IdType="pubmed">31599037</ArticleId></ArticleIdList></Reference><Reference><Citation>White MA, Kim E, Duffy A, Adalbert R, Phillips BU, Peters OM, et al. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat Neurosci. 2018;21(4):552&#x2013;63. doi: 10.1038/s41593-018-0113-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0113-5</ArticleId><ArticleId IdType="pmc">PMC5884423</ArticleId><ArticleId IdType="pubmed">29556029</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugai A, Kato T, Koyama A, Koike Y, Konno T, Ishihara T, et al. Non-genetically modified models exhibit TARDBP mRNA increase due to perturbed TDP-43 autoregulation. Neurobiol Dis. 2019;130:104534. doi: 10.1016/j.nbd.2019.104534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.104534</ArticleId><ArticleId IdType="pubmed">31310801</ArticleId></ArticleIdList></Reference><Reference><Citation>Koyama A, Sugai A, Kato T, Ishihara T, Shiga A, Toyoshima Y, et al. Increased cytoplasmic TARDBP mRNA in affected spinal motor neurons in ALS caused by abnormal autoregulation of TDP-43. Nucleic Acids Res. 2016;44(12):5820&#x2013;36. doi: 10.1093/nar/gkw499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw499</ArticleId><ArticleId IdType="pmc">PMC4937342</ArticleId><ArticleId IdType="pubmed">27257061</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, De Conti L, Avendano-Vazquez SE, Dhir A, Romano M, D&#x2019;Ambrogio A, et al. TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J. 2011;30(2):277&#x2013;88. doi: 10.1038/emboj.2010.310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2010.310</ArticleId><ArticleId IdType="pmc">PMC3025456</ArticleId><ArticleId IdType="pubmed">21131904</ArticleId></ArticleIdList></Reference><Reference><Citation>Avendano-Vazquez SE, Dhir A, Bembich S, Buratti E, Proudfoot N, Baralle FE. Autoregulation of TDP-43 mRNA levels involves interplay between transcription, splicing, and alternative polyA site selection. Genes Dev. 2012;26(15):1679&#x2013;84. doi: 10.1101/gad.194829.112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.194829.112</ArticleId><ArticleId IdType="pmc">PMC3418585</ArticleId><ArticleId IdType="pubmed">22855830</ArticleId></ArticleIdList></Reference><Reference><Citation>Bembich S, Herzog JS, De Conti L, Stuani C, Avendano-Vazquez SE, Buratti E, et al. Predominance of spliceosomal complex formation over polyadenylation site selection in TDP-43 autoregulation. Nucleic Acids Res. 2014;42(5):3362&#x2013;71. doi: 10.1093/nar/gkt1343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkt1343</ArticleId><ArticleId IdType="pmc">PMC3950720</ArticleId><ArticleId IdType="pubmed">24369426</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki H, Matsuoka M. hnRNPA1 autoregulates its own mRNA expression to remain non-cytotoxic. Mol Cell Biochem. 2017;427(1&#x2013;2):123&#x2013;31. doi: 10.1007/s11010-016-2904-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11010-016-2904-x</ArticleId><ArticleId IdType="pubmed">28000042</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3(7):research0034.1&#x2013;.11. doi: 10.1186/gb-2002-3-7-research0034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2002-3-7-research0034</ArticleId><ArticleId IdType="pmc">PMC126239</ArticleId><ArticleId IdType="pubmed">12184808</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>